Tivozanib gets NICE nod for first-line treatment of advanced RCC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The United Kingdom’s National Institute for Health and Care Excellence has published a Final Appraisal Determination recommending FOTIVDA (tivozanib) for the first line treatment of adult patients with advanced renal cell carcinoma.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login